On August 10, 2023, OptiNose, Inc. projected that their net revenues for FY23 XHANCE would range between $64M-$70M, surpassing their previous estimate of $62M-$68M. Moreover, they anticipate the average net revenue per prescription for XHANCE in the full year of 2023 to be approximately $200.
During the first quarter of 2023, OptiNose recorded $11.8 million in net revenue from XHANCE, which represented a decline compared to the same period in 2022. However, in the second quarter of 2023, OptiNose announced a preliminary figure of $19.5 million in net revenue for XHANCE.
https://beststocks.com/optinose-inc-expects-increased-net-revenues-f/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.